Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study

@inproceedings{Tezuka2013PhaseIC,
  title={Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study},
  author={T. Tezuka and Chikuma Hamada and Hideyuki Ishida and Mitsuru Ooshiro and Hiroshi Matsuoka and Shingo Kawasaki and Hideyuki Mishima and Kotaro Maeda and Junichi Sakamoto and Keiji Koda},
  booktitle={Investigational New Drugs},
  year={2013}
}
Purpose Continuous treatment with FOLFOX therapy is associated with peripheral nerve toxicity, and to improve this inconvenient side effect various methods of administration are being investigated. A regimen of intermittent oxaliplatin administration by continuous infusion therapy, i.e., modified FOLFOX7 (mFOLFOX7) + bevacizumab, was designed with the goal of alleviating severe peripheral nerve disorders and hematological toxicity. A phase II clinical study was conducted to evaluate the… CONTINUE READING